Baumgart E, Fahimi H D, Stich A, Völkl A
Institute for Anatomy and Cell Biology II, University of Heidelberg, Im Neuenheimer Feld 307, 69120 Heidelberg, Federal Republic of Germany.
J Biol Chem. 1996 Feb 16;271(7):3846-55. doi: 10.1074/jbc.271.7.3846.
The subcellular localization of l-lactate dehydrogenase (LDH) in rat hepatocytes has been studied by analytical subcellular fractionation combined with the immunodetection of LDH in isolated subcellular fractions and liver sections by immunoblotting and immunoelectron microscopy. The results clearly demonstrate the presence of LDH in the matrix of peroxisomes in addition to the cytosol. Both cytosolic and peroxisomal LDH subunits have the same molecular mass (35.0 kDa) and show comparable cross-reactivity with an anti-cytosolic LDH antibody. As revealed by activity staining or immunoblotting after isoelectric focussing, both intracellular compartments contain the same liver-specific LDH-isoforms (LDH-A4 > LDH-A3B) with the peroxisomes comprising relatively more LDH-A3B than the cytosol. Selective KCl extraction as well as resistance to proteinase K and immunoelectron microscopy revealed that at least 80% of the LDH activity measured in highly purified peroxisomal fractions is due to LDH as a bona fide peroxisomal matrix enzyme. In combination with the data of cell fractionation, this implies that at least 0.5% of the total LDH activity in hepatocytes is present in peroxisomes. Since no other enzymes of the glycolytic pathway (such as phosphoglucomutase, phosphoglucoisomerase, and glyceraldehyde-3-phosphate dehydrogenase) were found in highly purified peroxisomal fractions, it does not seem that LDH in peroxisomes participates in glycolysis. Instead, the marked elevation of LDH in peroxisomes of rats treated with the hypolipidemic drug bezafibrate, concomitantly to the induction of the peroxisomal beta-oxidation enzymes, strongly suggests that intraperoxisomal LDH may be involved in the reoxidation of NADH generated by the beta-oxidation pathway. The interaction of LDH and the peroxisomal palmitoyl-CoA beta-oxidation system could be verified in a modified beta-oxidation assay by adding increasing amounts of pyruvate to the standard assay mixture and recording the change of NADH production rates. A dose-dependent decrease of NADH produced was simulated with the lowest NADH value found at maximal LDH activity. The addition of oxamic acid, a specific inhibitor of LDH, to the system or inhibition of LDH by high pyruvate levels (up to 20 mm) restored the NADH values to control levels. A direct effect of pyruvate on palmitoyl-CoA oxidase and enoyl-CoA hydratase was excluded by measuring those enzymes individually in separate assays. An LDH-based shuttle across the peroxisomal membrane should provide an efficient system to regulate intraperoxisomal NAD+/NADH levels and maintain the flux of fatty acids through the peroxisomal beta-oxidation spiral.
通过亚细胞分级分离分析,并结合免疫印迹和免疫电子显微镜技术对分离的亚细胞组分及肝组织切片中的l-乳酸脱氢酶(LDH)进行免疫检测,研究了大鼠肝细胞中LDH的亚细胞定位。结果清楚地表明,除了胞质溶胶外,过氧化物酶体基质中也存在LDH。胞质和过氧化物酶体中的LDH亚基具有相同的分子量(35.0 kDa),并且与抗胞质LDH抗体显示出相当的交叉反应性。通过等电聚焦后的活性染色或免疫印迹发现,两个细胞内区室都含有相同的肝脏特异性LDH同工型(LDH-A4 > LDH-A3B),过氧化物酶体中所含的LDH-A3B比胞质溶胶相对更多。选择性KCl提取以及对蛋白酶K的抗性和免疫电子显微镜显示,在高度纯化的过氧化物酶体组分中测得的LDH活性至少80%归因于作为真正过氧化物酶体基质酶的LDH。结合细胞分级分离的数据,这意味着肝细胞中至少0.5%的总LDH活性存在于过氧化物酶体中。由于在高度纯化的过氧化物酶体组分中未发现糖酵解途径的其他酶(如磷酸葡萄糖变位酶、磷酸葡萄糖异构酶和甘油醛-3-磷酸脱氢酶),过氧化物酶体中的LDH似乎不参与糖酵解。相反,用降血脂药物苯扎贝特处理的大鼠过氧化物酶体中LDH的显著升高,与过氧化物酶体β-氧化酶的诱导同时发生,强烈表明过氧化物酶体内的LDH可能参与β-氧化途径产生的NADH的再氧化。通过向标准测定混合物中添加越来越多的丙酮酸并记录NADH产生速率的变化,在改良的β-氧化测定中可以验证LDH与过氧化物酶体棕榈酰辅酶Aβ-氧化系统的相互作用。在最大LDH活性时发现最低的NADH值,模拟了产生的NADH的剂量依赖性降低。向系统中添加LDH的特异性抑制剂草氨酸或高丙酮酸水平(高达20 mM)对LDH的抑制使NADH值恢复到对照水平。通过在单独的测定中分别测量这些酶,排除了丙酮酸对棕榈酰辅酶A氧化酶和烯酰辅酶A水合酶的直接作用。基于LDH的穿梭穿过过氧化物酶体膜应该提供一个有效的系统来调节过氧化物酶体内的NAD+/NADH水平,并维持脂肪酸通过过氧化物酶体β-氧化螺旋的通量。